<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426958</url>
  </required_header>
  <id_info>
    <org_study_id>1200.151</org_study_id>
    <secondary_id>2011-001803-11</secondary_id>
    <nct_id>NCT01426958</nct_id>
  </id_info>
  <brief_title>Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects</brief_title>
  <official_title>Relative Bioavailability of a Single Oral Dose of 40 mg Afatinib Given Alone Compared to Concomitant and Timed Administration of Multiple Oral Doses of Ritonavir - an Open-label, Randomised, Three-way Crossover Trial in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To study the effect of the P-glycoprotein inhibitor ritonavir on the pharmacokinetics (PK) of
      afatinib depending on the timepoint of ritonavir administration
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve From 0 to tz (AUC0-tz)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post</time_frame>
    <description>AUC0-tz represents the area under the concentration curve of the analyte in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post</time_frame>
    <description>Cmax represents the maximum concentration of the analyte in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve From 0 to ∞ Hours (AUC0-∞)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post</time_frame>
    <description>AUC0-∞ represents the area under the concentration curve of the analyte in plasma from 0 extrapolated to infinity.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet afatinib single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>standard therapeutic dose</description>
    <arm_group_label>treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir + afatinib</intervention_name>
    <description>simultaneous intake of ritonavir and afatinib on second treatment day</description>
    <arm_group_label>treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir + afatinib</intervention_name>
    <description>on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet</description>
    <arm_group_label>treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. healthy male subjects

        Exclusion criteria:

        1. any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.151.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2013</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>This is an open-label, randomized, three-way crossover clinical phase I trial in healthy volunteers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>This is an open-label, randomized, three-way crossover clinical phase I trial in healthy volunteers.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Curve From 0 to tz (AUC0-tz)</title>
        <description>AUC0-tz represents the area under the concentration curve of the analyte in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte.</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post</time_frame>
        <population>This subject set includes all evaluable subjects of the treated set who were assigned to the final dose groups and who provide at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib</title>
            <description>Subjects were treated with a single dose of Afatinib 40mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib + Concomittant Rtv</title>
            <description>Subjects were treated with Ritonavir (Rtv) 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 with third Rtv dose.</description>
          </group>
          <group group_id="O3">
            <title>Afatinib + Timed Rtv</title>
            <description>Subjects were treated with Rtv 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 six hours prior to third Rtv dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to tz (AUC0-tz)</title>
          <description>AUC0-tz represents the area under the concentration curve of the analyte in plasma from 0 to the time of the last quantifiable plasma contentration of the analyte.</description>
          <population>This subject set includes all evaluable subjects of the treated set who were assigned to the final dose groups and who provide at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392" spread="26.2"/>
                    <measurement group_id="O2" value="478" spread="27.9"/>
                    <measurement group_id="O3" value="438" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.1009</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>119.30</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>112.239</ci_lower_limit>
            <ci_upper_limit>126.811</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0009</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>110.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.837</ci_lower_limit>
            <ci_upper_limit>117.006</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>91.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.519</ci_lower_limit>
            <ci_upper_limit>97.614</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax)</title>
        <description>Cmax represents the maximum concentration of the analyte in plasma.</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post</time_frame>
        <population>This subject set includes all evaluable subjects of the treated set who were assigned to the final dose groups and who provide at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib</title>
            <description>Subjects were treated with a single dose of Afatinib 40mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib + Concomittant Rtv</title>
            <description>Subjects were treated with Ritonavir (Rtv) 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 with third Rtv dose.</description>
          </group>
          <group group_id="O3">
            <title>Afatinib + Timed Rtv</title>
            <description>Subjects were treated with Rtv 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 six hours prior to third Rtv dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax)</title>
          <description>Cmax represents the maximum concentration of the analyte in plasma.</description>
          <population>This subject set includes all evaluable subjects of the treated set who were assigned to the final dose groups and who provide at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="33.5"/>
                    <measurement group_id="O2" value="20.7" spread="29.4"/>
                    <measurement group_id="O3" value="20.7" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.681</ci_lower_limit>
            <ci_upper_limit>112.002</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0012</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>105.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.425</ci_lower_limit>
            <ci_upper_limit>114.530</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>99.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.328</ci_lower_limit>
            <ci_upper_limit>106.610</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under Curve From 0 to ∞ Hours (AUC0-∞)</title>
        <description>AUC0-∞ represents the area under the concentration curve of the analyte in plasma from 0 extrapolated to infinity.</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours post</time_frame>
        <population>This subject set includes all evaluable subjects of the treated set who were assigned to the final dose groups and who provide at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib</title>
            <description>Subjects were treated with a single dose of Afatinib 40mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib + Concomittant Rtv</title>
            <description>Subjects were treated with Ritonavir (Rtv) 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 with third Rtv dose.</description>
          </group>
          <group group_id="O3">
            <title>Afatinib + Timed Rtv</title>
            <description>Subjects were treated with Rtv 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 six hours prior to third Rtv dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve From 0 to ∞ Hours (AUC0-∞)</title>
          <description>AUC0-∞ represents the area under the concentration curve of the analyte in plasma from 0 extrapolated to infinity.</description>
          <population>This subject set includes all evaluable subjects of the treated set who were assigned to the final dose groups and who provide at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426" spread="22.8"/>
                    <measurement group_id="O2" value="515" spread="27.5"/>
                    <measurement group_id="O3" value="475" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0702</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>118.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>111.712</ci_lower_limit>
            <ci_upper_limit>125.822</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0005</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>110.76</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>104.936</ci_lower_limit>
            <ci_upper_limit>116.913</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative bioavailability</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <p_value_desc>P-value for ratio outside interval 0.8-1.25</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Adjusted geometric mean ratio</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>92.46</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.928</ci_lower_limit>
            <ci_upper_limit>98.341</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration of trial medication until 28 days after last administration of trial medication</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Afatinib</title>
          <description>Subjects were treated with a single dose of Afatinib 40mg on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Afatinib + Concomittant Rtv</title>
          <description>Subjects were treated with Ritonavir (Rtv) 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 with third Rtv dose.</description>
        </group>
        <group group_id="E3">
          <title>Afatinib + Timed Rtv</title>
          <description>Subjects were treated with Rtv 2x100mg twice daily (bid) on Days -1, 1 and 2 and with a single dose of Afatinib 40mg on Day 1 six hours prior to third Rtv dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

